Table 1. Patient characteristics.
| With Cachexia | Without Cachexia | p-value | ||
| n = 9 | n = 12 | |||
| Age | (years) | 72 (39–76) | 64.5 (36–77) | 0.57 |
| Gender | Male/Female | 8/1 | 8/4 | 0.25 |
| PS | 0/1/2/3 | 0/5/3/1 | 4/8/0/0 | 0.005 |
| Stage | IVA/IVB | 5/4 | 5/7 | 0.54 |
| BW loss rate | (%) | 13.4 (10.2–30.8) | 2.5 (−5.2–4.6) | 0.0001 |
| Body weight | (kg) | 55.6 (45.0–77.0) | 57.5 (44.6–77.3) | 0.48 |
| Body mass index | 22.6 (18.2–25.8) | 19.7 (16.5–26.1) | 0.15 | |
| Anorexia | Gr 0/1/2/3 | 0/8/0/1 | 5/7/0/0 | 0.02 |
| Prior treatment | (No/Yes) | 8/1 | 11/1 | 0.83 |
| Laboratory data | ||||
| WBC | (/µL) | 5100 (4100–17600) | 5850 (3000–111600) | 0.97 |
| Hb | (g/dL) | 11.9 (9.3–15.2) | 13.7 (11.3–14.6) | 0.20 |
| TP | (g/dL) | 6.4 (4.8–6.8) | 6.7 (6.0–7.5) | 0.15 |
| Alb | (g/dL) | 3.2 (2.1–4.7) | 3.9 (3.5–4.4) | 0.14 |
| LDH | (U/L) | 169 (125–228) | 179 (127–340) | 0.27 |
| TChol | (mg/dL) | 131 (99–167) | 187 (136–205) | 0.001 |
| LDL | (mg/dL) | 72 (45–91) | 100 (71–143) | 0.02 |
| HDL | (mg/dL) | 42 (22–73) | 53 (29–93) | 0.20 |
| TG | (mg/dL) | 90 (44–112) | 112 (62–159) | 0.09 |
| CRP | (mg/dL) | 1.9 (0.1–2.64) | 0.55 (0.1–6.97) | 0.89 |
| HbA1c | (%) | 5.7 (4.8–6.5) | 6.4 (4.6–7.3) | 0.11 |
| Tumor marker | ||||
| CEA | (ng/mL) | 5.0 (1.4–29.2) | 4.7 (2.0–883.7) | 1.00 |
| CA19-9 | (U/mL) | 271 (5–1974) | 379 (1–80673) | 0.43 |
| DUPAN-2 | (U/mL) | 560 (33–230000) | 605 (25–140000) | 0.89 |
Abbreviations: PS, Eastern Cooperative Oncology Group performance status; BW loss rate, body weight loss rate over 6 months; TChol, total Cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TG, triglyceride; CRP, C-reactive protein.